PCC and soon BXN is all about the Hunter Immunology IP.The Phase IIb trial results will be released soon.The trial was completed at the end of the last Australian winter.
A positive result (for an oral vaccine to treat COPD-Chronic Obstructive Pulmonary Disorder,the new name for emphysema and chronic bronchitis) would be very very positive for PCC holders.It would not only suggest a very valuable product for a huge health problem,but would also offer proof of concept for the IP in many other disease areas.
The old PCC/probiotics market is not the main game at all.
PCC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
